Ananda Pharma Cross-Lists on OTCQB to Expand U.S. Reach

Ananda Pharma, a UK-based biopharmaceutical company focused on cannabinoid medicines, has successfully secured an additional trading venue for its ordinary shares through the OTCQB Venture Market in the United States. The company, already listed on the Aquis Stock Exchange in London, began its U.S. trading under the ticker 'ANANF' on April 14, 2025. This strategic cross-listing aims to capture a wider investment audience and enhance the company’s visibility in the American market, known for its significant pharmaceutical sector. While no new capital was raised through this move, U.S. investors will benefit from access to Ananda's shares priced in U.S. Dollars during the hours convenient for U.S. trading. Legal advisory for this endeavor was provided by Orrick, indicating a careful navigation through regulatory and market complexities to achieve this listing.